Showing results (41-50 of 184) with videos related to

Sort By:
Pageof 19
Biopharmaceutics & Drug Disposition|September 3, 2017
Impact of enzalutamide and its main metabolite N-desmethyl enzalutamide on pharmacokinetically important drug metabolizing enzymes and drug transportersJohanna Weiss, Jutta Kocher, Corina Mueller, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 1, 2010
Telmisartan: a review of its pharmacodynamic and pharmacokinetic propertiesSylvia Deppe, Rainer H Böger, Johanna Weiss, et al.
Analytical Biochemistry|June 22, 2016
Bortezomib and ixazomib protect firefly luciferase from degradation and can flaw respective reporter gene assaysJonas Philipp Becker, Jannick Robert Clemens, Dirk Theile, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 27, 2007
Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitroCaroline Henrike Storch, Robert Ehehalt, Walter Emil Haefeli, et al.
Pharmaceutics|March 2, 2016
Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug InteractionsJohanna Weiss, Thomas Gajek, Bruno Christian Köhler, et al.
Analytical Biochemistry|December 3, 2014
Fetal calf sera can distort cell-based luminescent proteasome assays through heat-resistant chymotrypsin-like activitySusan Dettmer, Dirk Theile, Anja Seckinger, et al.
The Journal of Pharmacy and Pharmacology|September 14, 2013
In-vitro evaluation of chronic alcohol effects on expression of drug-metabolizing and drug-transporting proteinsDirk Theile, Tobias T Schmidt, Walter E Haefeli, et al.
The Journal of Pharmacy and Pharmacology|August 11, 2015
Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell linesDirk Theile, David Allendorf, Bruno Christian Köhler, et al.
British Journal of Clinical Pharmacology|March 3, 2012
Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidineBarbara Grün, Ulrike Merkel, Klaus-Dieter Riedel, et al.
Pharmaceutics|June 2, 2021
Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition GenesDirk Theile, Lelia Wagner, Cindy Bay, et al.
Pageof 19